They looked exactly alike—tall, slightly scruffy gentlemen with denim overalls lightly stained with dirt and oil, with dusty trucker hats to match. The only difference was that one wore a red checkered shirt and the other wore a green one. Yet these similarities were deceptive. The one closest to me was the patient, the one…
Guest columnists Dr. Daniel Solomon & Dr. Andrew Concoff discuss the potential of technology, such as mobile health apps, to enhance remote care & improve access for underserved patients.
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
According to a new study, fibromyalgia prevalence is elevated in PsA and is associated with elevated disease measures, confounding reliable disease assessment for treat-to-target goals.
At a Great Debate session, speakers discussed whether mixed connective tissue disease is a distinct disease entity in rheumatology.
Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…
In this Review Course at ACR Convergence 2024, Iain McInnes, PhD, FRCP, discussed some of the challenges of RA: Remission is drug maintained, multimorbidity abounds, treatment strategies can be complex, & prevention is not yet possible.
Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.
Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.
Can a treat-to-target strategy achieve better outcomes for patients with spondyloarthritis? Insights from the latest data.